With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Executive Summary
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.
You may also be interested in...
Hep C Cost-Effectiveness Study Supports Limiting Incivek Use
Study presented at AASLD provides evidence of the potential value of genotyping patients prior to treatment with new protease inhibitors; Medco ready to start testing program.
Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors
Boehringer Ingelheim GMBH and Eli Lilly & Co. are likely to play up simplicity of dosing for the just-approved DPP-4 inhibitor Tradjenta (linagliptin) in a launch planned for the end of May, and expect to price the drug on par with others in the class.
Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors
Boehringer Ingelheim GMBH and Eli Lilly & Co. are likely to play up simplicity of dosing for the just-approved DPP-4 inhibitor Tradjenta (linagliptin) in a launch planned for the end of May, and expect to price the drug on par with others in the class.